Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Adam S. Fleisher, Abhinay D. Joshi, Karen L. Sundell, Yun Fei Chen, Sara Kollack-Walker, Ming Lu, Sherry Chen, Michael D. Devous, John Seibyl, Kenneth Marek, Eric R. Siemers, Mark A. Mintun

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Introduction: We compared subject-specific white matter (SSWM) and whole cerebellum (CBL) reference regions for power to detect longitudinal change in amyloid positron emission tomography signal. Methods: Positive florbetapir positron emission tomography scans were analyzed from participants (66 placebo treated and 63 solanezumab treated) with mild dementia caused by Alzheimer's disease from the EXPEDITION and EXPEDITION2 studies. For comparison to CBL, a second normalization was performed on longitudinal data using an SSWM correction factor (SSWM normalization ratio [SSWMnr]). Analysis of covariance assessed baseline to 18-month change between treatment with solanezumab and placebo. Sample and effect size estimations provided magnitude of observed treatment changes. Results: Longitudinal percent change between placebo and solanezumab using CBL was not significant (P = .536) but was significant for SSWMnr (P = .042). Compared with CBL, SSWMnr technique increased the power to detect a treatment difference, more than tripling the effect size and reducing the sample size requirements by 85% to 90%. Discussion: Adjusting longitudinal standardized uptake value ratios with an SSWM reference region in these antiamyloid treatment trials increased mean change detection and decreased variance resulting in the substantial improvement in statistical power to detect change.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2017

Keywords

  • Alzheimer's disease
  • Disease course
  • Florbetapir
  • Growth mixture model
  • Reference region
  • Serial PET imaging
  • Solanezumab
  • Trajectory

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials'. Together they form a unique fingerprint.

  • Cite this

    Fleisher, A. S., Joshi, A. D., Sundell, K. L., Chen, Y. F., Kollack-Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J., Marek, K., Siemers, E. R., & Mintun, M. A. (Accepted/In press). Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2017.02.009